Polynovo Ltd Total Assets

Latest as of December 2025: AU$123.37 Million AUD ≈ $87.29 Million USD

Polynovo Ltd total assets. Based on the latest financial reports, Polynovo Ltd (PNV) holds total assets worth AU$123.37 Million AUD (≈ $87.29 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Polynovo Ltd (PNV) market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Polynovo Ltd (1999–2025)

Total assets of Polynovo Ltd from 1999 to 2025. This chart illustrates how Polynovo Ltd's total assets have evolved over time, based on quarterly financial data. See Polynovo Ltd stock quote for real-time trading data and today's change.

Polynovo Ltd - Asset Composition Analysis

Polynovo Ltd Total Assets Breakdown (June 2025)

Polynovo Ltd total assets breakdown as of June 2025. Polynovo Ltd's total assets of AU$123.37 Million consist of 60.5% current assets and 39.5% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$6.91 Million 26.3%
Accounts Receivable AU$24.39 Million 19.1%
Inventory AU$14.49 Million 11.4%
Property, Plant & Equipment AU$38.22 Million 30.0%
Intangible Assets AU$661.00K 0.5%
Goodwill AU$0.00 0.0%

Asset Composition Trend (1999–2025)

This chart illustrates how Polynovo Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Polynovo Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Polynovo Ltd's current assets represent 60.5% of total assets in 2025, a decrease from 78.7% in 1999.
  • Cash Position: Cash and equivalents constituted 26.3% of total assets in 2025, down from 76.7% in 1999.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 1999.
  • Asset Diversification: The largest asset category is property, plant & equipment at 30.0% of total assets.

Polynovo Ltd Competitors by Total Assets

Key competitors of Polynovo Ltd based on total assets are shown below.

Company Country Total Assets
HOB Biotech Group Corp Ltd
SHG:688656
China CN¥916.43 Million
L&C Bio Co. Ltd
KQ:290650
Korea ₩497.94 Billion
Applied BioCode
TW:6598
Taiwan NT$1.03 Billion
Oncosil Medical Ltd
AU:OSL
Australia AU$7.13 Million
Sequana Medical NV
BR:SEQUA
Belgium €14.57 Million
Cleo Diagnostics Ltd
AU:COV
Australia AU$9.96 Million
Radiant Innovation
TWO:3373
Taiwan NT$859.52 Million
MedX Health Corp
V:MDX
Canada CA$1.26 Million

Polynovo Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.03 3.46 2.28
Quick Ratio 2.51 2.84 2.04
Cash Ratio 0.00 0.00 0.00
Working Capital AU$46.41 Million AU$56.09 Million AU$8.32 Million

Polynovo Ltd - Advanced Valuation Insights

This section examines the relationship between Polynovo Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 8.39
Latest Market Cap to Assets Ratio 3.36
Asset Growth Rate (YoY) 17.2%
Total Assets AU$127.41 Million
Market Capitalization $427.71 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Polynovo Ltd's assets at a significant premium (3.36x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Polynovo Ltd's assets grew by 17.2% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Polynovo Ltd (1999–2025)

The table below shows the annual total assets of Polynovo Ltd from 1999 to 2025.

Year Total Assets Change
2025-06-30 AU$127.41 Million
≈ $90.15 Million
+17.19%
2024-06-30 AU$108.72 Million
≈ $76.93 Million
+17.38%
2023-06-30 AU$92.62 Million
≈ $65.54 Million
+164.85%
2022-06-30 AU$34.97 Million
≈ $24.74 Million
-8.78%
2021-06-30 AU$38.34 Million
≈ $27.13 Million
+1.27%
2020-06-30 AU$37.86 Million
≈ $26.79 Million
+34.11%
2019-06-30 AU$28.23 Million
≈ $19.97 Million
-5.34%
2018-06-30 AU$29.82 Million
≈ $21.10 Million
+147.36%
2017-06-30 AU$12.06 Million
≈ $8.53 Million
-24.77%
2016-06-30 AU$16.02 Million
≈ $11.34 Million
+97.21%
2015-06-30 AU$8.13 Million
≈ $5.75 Million
-13.68%
2014-06-30 AU$9.41 Million
≈ $6.66 Million
+9.22%
2013-06-30 AU$8.62 Million
≈ $6.10 Million
-3.26%
2012-06-30 AU$8.91 Million
≈ $6.30 Million
-24.32%
2011-06-30 AU$11.77 Million
≈ $8.33 Million
-21.64%
2010-06-30 AU$15.02 Million
≈ $10.63 Million
-13.11%
2009-06-30 AU$17.29 Million
≈ $12.23 Million
+0.73%
2008-06-30 AU$17.16 Million
≈ $12.14 Million
-22.05%
2007-06-30 AU$22.02 Million
≈ $15.58 Million
-11.75%
2006-06-30 AU$24.95 Million
≈ $17.65 Million
+33.51%
2005-06-30 AU$18.69 Million
≈ $13.22 Million
+0.19%
2004-06-30 AU$18.65 Million
≈ $13.20 Million
+149.53%
2003-06-30 AU$7.47 Million
≈ $5.29 Million
-40.75%
2002-06-30 AU$12.61 Million
≈ $8.93 Million
+74.65%
2001-06-30 AU$7.22 Million
≈ $5.11 Million
-39.62%
2000-06-30 AU$11.96 Million
≈ $8.46 Million
+69.01%
1999-06-30 AU$7.08 Million
≈ $5.01 Million
--

About Polynovo Ltd

AU:PNV Australia Medical Devices
Market Cap
$427.71 Million
AU$604.49 Million AUD
Market Cap Rank
#12762 Global
#327 in Australia
Share Price
AU$0.88
Change (1 day)
-5.41%
52-Week Range
AU$0.82 - AU$1.29
All Time High
AU$4.01
About

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for her… Read more